Page 150 - CW E-Magazine (30-4-2024)

Top Stories Pharmaceuticals

RESPONSIBLE CORPORATES COLLABORATION
Majority of top-100 companies making disclosures Biocon signs deal with Biomm to commercialise

about carbon emissions: PwC India diabetes drug in Brazil

Supplementing the efforts of the gating India’s Transition to Sustainability’. their information on leadership indica- Biocon has signed an exclusive The addressable market for Semaglutide Biomm focuses on developing,
Indian Government to achieve a net-zero This, it added, “sheds light on how Indian tors, and 49% have increased their energy licensing and supply agreement that in Brazil stands at around $580-mn, manufacturing, and commercialising
emission target by 2070, as many as 51% businesses are taking a step further in ESG consumption from renewable sources. will allow Brazil’s Biomm SA to com- based on IQVIA Moving Annual Total complex biotech and biosimilar drug
of the top-100 companies have started reporting as Scope 3 emissions are crucial According to the report, the key initiatives mercialise the Bengaluru-based com- for the fourth quarter of 2023. products at a production facility in
making disclosures on a voluntary basis to understand an entity’s net zero journey.” that led to a reduction in emissions inclu- pany’s drug Semaglutide (Ozempic) to Nova Lima. According to Biomm,
about carbon emissions, says a PwC India ded transitioning to energy-effi cient tech- control type-2 diabetes in adults. “Our partnership with Biomm marks Brazil ranks fi fth globally in diabetes
survey. The survey further said that “With the BRSR becoming a man- nologies such as LEDs, adopting effi cient another important step forward in our prevalence.
about 31% of the respondent companies datory report for businesses, ESG con- air-conditioning, ventilation, and heating Biocon will undertake the deve- strategy to expand our global footprint
have disclosed their net-zero targets. siderations have become key strategic systems, shifting to renewable sources for lopment, manufacturing, and supply beyond the US and Europe for peptides. “We have, therefore, prioritised
priorities in boardroom discussions. This securing energy needs, purchasing carbon of drug products and Biomm will be This is also in line with our growth stra- strategic partnerships to expand the
The government and the regulators is a testimony of the enhanced awareness offsets, and entering into off-site power responsible for obtaining regulatory tegy of bringing to market a portfolio population’s access to advanced treat-
have introduced new regulations pertain- of the importance of sustainability and purchase agreements. approval and commercialisation in of complex, GLP-1 drug-device com- ments for this disease and enhance
ing to ESG (environmental, social and responsible business practices,” said the Brazilian market, according to the bination products,” said Mr. Siddharth the quality of life for people,” said
governance) for businesses. This BRSR Mr. Sambitosh Mohapatra, Partner & “As India commits to achieve its net agreement between the two companies. Mittal, CEO and MD of Biocon. Mr. Heraldo Marchezini, CEO of Biomm.
(Business Responsibility and Sustainabi- Leader, ESG, PwC India. ESG reporting zero vision by 2070, the business sector
lity Reporting) framework is a mandatory through the BRSR has ushered in greater is being viewed as a critical enabler in OVERACTIVE BLADDER MEDICATION
disclosure mechanism for top 1,000-listed transparency and a holistic view of a furthering this ambition,” it said. India’s tran-
companies to report their performance on business’s environmental and societal sition to BRSR Core positions the nation Lupin, Zydus launch mirabegron extended-release
ESG aspects and demonstrate their com- impact, thus enabling investors and other as a frontrunner in the global transition
mitment to responsible business practices. stakeholders to form key decisions through towards a more credible and transparent tablets in US
The BRSR Core is a sub-set of the BRSR, an ESG lens, make comparisons across sustainability reporting landscape, it added.
consisting of a set of Key Performance companies and sectors, and track progress Pharma fi rms – Lupin and Zydus Pharma Global Development, Inc. It USFDA’s nod to market the 50-mg tablets
Indicators (KPIs)/metrics under nine over time, PwC India said. The report has analysed the publicly Lifesciences – have announced the launch is indicated for the treatment of over- of the drug and is set to launch it soon.
ESG attributes. “51% of India’s top 100 accessible BRSR reports of top 100 com- of Mirabegron extended-release tablets, active bladder (OAB) with symptoms
listed companies by market capitalisation The survey further said 44% of the panies (Nifty 50 companies and NEXT 25-mg, in the US, after having received of urge urinary incontinence, urgency Mirabegron Extended-Release
disclosed their Scope 3 data for FY23, top 100 listed companies conducted the 50 listed companies) and their response to fi nal approvals from the United States and urinary frequency. Tablets USP 25mg and 50mg had
despite it being a voluntary disclosure in life-cycle assessment of their products or the regulatory requirement of mandatory Food and Drug Administration (US FDA). annual sales of US$2.42-bn in the
BRSR,” said the PwC report titled ‘Navi- services, 89% of the companies disclosed reporting under the BRSR for FY23. Zydus said the drug will be manu- US (IQVIA MAT February 2024).
Mirabegron extended-release tablet factured at the group’s formulation The 25-mg tablets had estimated annual
GACL undertakes voter awareness campaign is a generic equivalent of Myrbetriq manufacturing facility in Ahmedabad sales of $1,019-mn in the US (IQVIA
extended-release tablets of Astellas SEZ. The company has also received MAT February 2024).
Gujarat Alkalies and Chemicals duty. Additionally, a specially
Ltd. (GACL), in collaboration with curated video song, released Complaint fi led against Natco Pharma in US
the Vadodara Collectorate and District by the District Collectorate
Election Offi ce, has conducted initia- for the occasion, played in the by Fresenius Kabi
tives to foster voter awareness and auditorium, amplifying the spirit Hyderabad-based Natco Pharma Pharma USA LLC (erstwhile Dash been acquired by Natco Pharma, Inc.
participation. of electoral engagement. has informed that a complaint has Pharmaceuticals LLC) in the District and had changed its name to Natco
been fi led against it at a district court Court of Delaware relating to the Pharma USA.
Under the Election Commission of “Through such efforts, in the US by Fresenius Kabi over marketing of Dash Pharmaceuticals’
India’s fl agship programme, “SVEEP” GACL sets a precedent for the marketing of Diazepam injection Diazepam Injection prefi lled syringe “Fresenius has not yet effectuated
(Systematic Voters’ Education and Elec- corporate citizenship and under- pre-fi lled syringe in the country. in the US, the company said in a regu- service of the complaint which is
toral Participation), a voter pledge was scores the vital role of the latory fi ling. Diazepam injection is required to commence the lawsuit,” the
undertaken at the corporate offi ce of tival, Pride of the Country” in the pre- industry in promoting democratic Fresenius Kabi USA, LLC and indicated in the treatment of anxiety, fi ling added. Natco Pharma intends
GACL in Vadodara (Gujarat). The event sence of senior executives and staff mem- values and civic engagement,” the Fresenius Kabi Deutschland GmbH muscle spasms, and alcohol with- to defend the matter accordingly, the
was celebrated in view of “Election Fes- bers who vowed to uphold their civic company said in a press note. have fi led a complaint against Natco drawal. Dash Pharmaceuticals had company said.

150 Chemical Weekly April 30, 2024 Chemical Weekly April 30, 2024 151

Contents Index to Advertisers Index to Products Advertised